Together, these findings show docetaxel increases expression of multiple pro-lymphangiogenic factors, including VEGFC and TNF-α, in the 4T1 tumor microenvironment, and these changes can be mitigated by the addition of anti-VEGFR3 therapy. The gene discussed is VEGFC; the disease is neoplasm.